Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Adrenalectomy
NCT ID: NCT03844477
Last Updated: 2019-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
25 participants
INTERVENTIONAL
2019-02-16
2019-05-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of Anterior Quadratus Lumborum Block at the Lateral Supra-arcuate Ligament Under Laparoscopic Direct Vision in Laparoscopic Renal Surgery
NCT06550869
Comparison of Two Techniques of Quadratus Lumborum Block
NCT05001802
The Analgesic Effect of Quadratus Lumborum Block and Its Postoperative Implication on Kidney Function
NCT04425174
Quadratus Lumborum Block as an Anesthetic Method for Percutaneous Nephrolithotomy
NCT04852874
Efficiency of the Quadratus Lumborum Block for Post-operative Analgesia in Abdominoplasty Surgery
NCT04670224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
single-injection QLB(quadratus lumborum block)
Single-injection of QLB with local anesthetic is given preoperatively
single-injection QLB(quadratus lumborum block)
Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion
Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan
Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified.
Placebo control
Single-injection of QLB with NS is given preoperatively
Placebo control
Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion
Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan
Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
single-injection QLB(quadratus lumborum block)
Inject 0.4ml/kg 0.5% ropivacaine between quadratus lumborum and psoas major without continuous local infusion
Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan
Device: PAJUNK StimuLong Drug: single dose ropivacaine 0.4ml/kg 0.5% ropivacaine given immediately after the correct position of the tip of the needle has been verified.
Placebo control
Inject 0.4ml/kg saline between quadratus lumborum and psoas major without continuous local infusion
Device: Ultrasound Scanner The curved (C1-5) probe of Ultrasound Scanner is used for scan
Device: PAJUNK StimuLong Drug: single dose 0.4ml/kg 0.9% NS. given immediately after the correct position of the tip of the needle has been verified.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American Society of Anesthesiologists physical statusⅠ-Ⅲ
* Undergo laparoscopic adrenalectomy
* Informed consent
Exclusion Criteria
* Coagulopathy, on anticoagulants
* Analgesics intake, history of substance abuse
* Participating in the investigation of another experimental agent
* Inability to properly describe postoperative pain to investigators (eg, language barrier, neuropsychiatric disorder)
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Cui Xulei
Attending physician
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xulei CUI, md
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking Union Medical College Hospital
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
cuixulei6
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.